This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cancer Neoantigen Vaccines

BOOKING CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
February 2, 2023 | 1-Day Digital Conference
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET
Key Sessions
Jenny Zilberberg
A personalized whole tumor-derived cell-based autologous immunotherapy platform for the treatment of solid tumors
Imvax Inc
Sari Pesonen
PeptiCRAd platform as a novel intratumoral fusion immunotherapy targeting heterogeneous antigen profile of solid tumors
Valo Therapeutics
Gritstone Bio
Neoantigen Immunotherapy For Solid Tumors – Molecular Responses and Clinical Benefit In End-Stage Patients – Moving Upstream
Gritstone Bio
Guilhem Richard
Distinguishing self-like neoantigens from non-self neoantigens for precision immunotherapies
Epivax, Inc.